Another alternative therapeutic approach for NAFLD in patients with remaining functional adipose tissue could be the up-regulation of endogenous adiponectin expression and/or its secretion induced by sustained weight loss or pharmacological agents, such as TZDs or SPPARMs, as described above [5]. Here, ADIPOQ is linked to metabolic dysfunction-associated steatotic liver disease.